Remdesivir ‘Disastrous’ as COVID Treatment, But Government Pays Hospitals to Use It

Remdesivir is an experimental drug developed by biotech company Gilead Sciences (under the brand name Veklury) in collaboration with the US Centers for Disease Control and Army Medical Research Institute of Infectious Diseases. Remdesivir, the primary COVID-19 drug approved for use in U.S. hospitals, routinely causes severe organ damage and, often, death, but U.S. government pays hospitals a 20% upcharge, plus an additional bonus, for using the Remdesivir protocol.

"The drug proved ineffective against the Ebola virus ... yet was still subsequently repurposed for SARS-CoV-2 coronavirus. News media prematurely reported that patients were responding to treatment.

Read more >